Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  ANALGESICS
A Global Strategic Business Report

This report analyzes the worldwide markets for Analgesics in Millions of US$. The major product segments analyzed are Internal Analgesics, (Aspirin, Acetaminophen, Ibuprofen, and Others (includes combination drugs)), and External Analgesics. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual forecasts are provided for each region for the period of 2001 through 2015. A ten-year historic analysis is also provided for these markets. The report profiles 139 companies including many key and niche players worldwide such as Bayer Consumer Care, Bristol-Myers Squibb Co., Johnson & Johnson, McNeil Consumer Healthcare, Novartis International AG, Pfizer, Inc., Reckitt Benckiser Group Plc, W. F. Young, Inc., Wyeth, and Wyeth Consumer Healthcare. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-5064  PAGES:    511
PRICE:    $3950  DATE:       October 2008
COMPANIES:  139  MARKET DATA TABLES:   163
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  ANALGESICS (Complete Report) Pages : 511   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS4$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
1. Internal Analgesics.....I-3
Aspirin.....I-3
Acetaminophen.....I-3
  
   Ibuprofen.....I-4
Others.....I-4
2. External Analgesics.....I-4
  
II. EXECUTIVE SUMMARY60$2250
  1. Global Analgesics Market Overview.....II-13 $300  
   Pain Therapeutic Market.....II-1
Analgesics Market - Offering Immense Potential .....II-1
Internal Analgesics - Riding on a Crest .....II-1
1$100
   Liquid Analgesics Register Rapid Growth.....II-2
Neuropathic Pain- Unexplored.....II-2
Ibuprofen Scoring High .....II-2
External Analgesics - In a slump .....II-2
1$100
   Boom in Demand for Topical Analgesic Patches.....II-3
1$100
  2. Product Overview.....II-48 $800  
   A Brief History .....II-4
Analgesics.....II-4
Definition.....II-4
Types of Pain.....II-4
Acute Pain.....II-4
1$100
   Chronic Pain.....II-5
Drugs Combating Pain.....II-5
Local Anesthetics.....II-5
Narcotic Opioids.....II-5
1$100
   Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).....II-6
Types of NSAIDS.....II-6
1$100
   Common NSAIDs.....II-7
Clinical Use........II-7
1$100
   Side Effects........II-8
Aspirin.....II-8
The Wonder Drug........II-8
1$100
   PolyAspirin: The Safer and More Potent Polymer Variant of Aspirin.....II-9
Mode of Action.....II-9
Contraindications.....II-9
Acetaminophen.....II-9
1$100
   Acetaminophen Protects Heart Muscle.....II-10
Acetaminophen Reduces Incidence of Ovarian Cancer.....II-10
Ibuprofen, Ketoprofen and Naproxen.....II-10
Combination Analgesics.....II-10
1$100
   Table 1: Opioid Analgesics Market: Percentage Share of Opioid / Acetaminophen Combination Products in the Opioid Script Volume (includes corresponding Graph/Chart).....II-11
OTC Analgesics: An Overview.....II-11
1$350
  3. Industry Dynamics.....II-122 $200  
   Escalating R&D Costs: A Boon or Bane?.....II-12
Timeline of the Drug Approval Process.....II-12
Cox II Crisis Tarnishes Industry Growth.....II-12
1$100
   Novel Therapies to Propel Opioid and Non-Opioid Therapies.....II-13
Rx-to-OTC Switch.....II-13
Why Consumers Prefer OTC Drugs?.....II-13
Development of Analgesic Tripeptides.....II-13
1$100
  4. Recent Clinical Trials.....II-141 $100  
   PLx Initiates Clinical Trial For Aspirin-PC.....II-14
Neurodiscovery Receives Approval for NSL-101 Phase II Clinical Trials.....II-14
1$100
  5. Product Innovations/Introductions.....II-155 $500  
   ProEthic Pharmaceuticals Releases Ibudone for Acute Pain Management.....II-15
Dr. Reddy’s Laboratories Introduces Supanac for Acute Pain Management.....II-15
Mallinckrodt Introduces Magnacet™ Tablets for Pain Management.....II-15
Wockhardt to Launch New Painkiller.....II-15
Paladin Labs and Labopharm Introduce Tridural™.....II-15
Shionogi & Co Introduces OxiNorm Powder 0.5%.....II-15
1$100
   McNeil Brings Chewable TYLENOL® GoTabs Tablets.....II-16
Barr Unveils Generic Version of ACTIQ®.....II-16
Novartis Launches Voltarol Pain-Eze Emulgel ......II-16
TheraQuest Launches TQ-1017.....II-16
Mentholatum Company Introduces WellPatch Deep Heat Patch .....II-16
1$100
   SSP and Mepha Launch Olfen Patch in Switzerland.....II-17
W.F. Young Expands Absorbine Jr®.....II-17
Pfizer Unveils Neurontin.....II-17
Ligand Pharmaceuticals Introduces Avinza in the US.....II-17
AlphaRx Introduces Flexogan.....II-17
Essere Introduces Roll-On Analgesic.....II-17
Novartis Introduces Topical Analgesic and Cough Suppressant in Sticks.....II-17
1$100
   SSL International Introduces Easy-To-Swallow Version of Paramol.....II-18
Janssen Launches Duragesic, a Narcotic Analgesic.....II-18
Abbott Laboratories Launches Narcotic Analgesic.....II-18
Ortho-McNeil Launches Flexeril.....II-18
Elkins-Sinn Launches Opioid Analgesic.....II-18
FH Faulding Launches Narcotic Analgesic, Kadian.....II-18
ICN Pharmaceuticals Launches Opioid Aanalgesic, Levo Dromoran.....II-18
Amarin Launches Motofen, a Narcotic Analgesic and Anti-Cholinergic.....II-18
1$100
   Purdue Pharma Launches MS Contin, a Narcotic Analgesic.....II-19
Able Laboratories Unveils New Versions of Acetaminophen and Hydrocodone
  Bitartrate.....II-19
Whitehall Launches Anadin Analgesic Tablets in South Africa.....II-19
Leiner Launches Ibuprofen Softgel Capsules.....II-19
Crookes Healthcare Launches Ibuprofen Singles for Children.....II-19
SSL International Launches Cuprofen Ibuprofen for Children.....II-19
Lloydspharmacy Launches Ibuprofen Suspension for Children.....II-19
1$100
  6. Recent Industry Activity.....II-208 $600  
   Bayer to Acquire Sagmel’s OTC Business.....II-20
E5 Pharma Receives Approval from FDA.....II-20
Pharmaceutical Associates Receives Approval from FDA.....II-20
Concord Receives New Drug Approvals.....II-20
Hisamitsu Receives Approval for SALONPAsÒ.....II-20
Johnson & Johnson Submits NDA to FDA.....II-20
Nycomed and Paladin Inks Joint-Promotion Agreement for Tridural.....II-20
1$100
   Akela Extends Agreement with Janssen.....II-21
Daiichi and Lead Chemical Receives Approval for LoxoninÒ Tape.....II-21
Tokio Marine Capital to Acquire Showa Yakuhin Kako.....II-21
Corgenix Collaborates with Randox Laboratories.....II-21
Corgenix Receives EPO Approval for Aspirin Resistance Method.....II-21
1$100
   IOL to Expand Production Capacity.....II-22
American Oriental Bioengineering Partners with China Aoxing.....II-22
Abraxis Takes Over Shimoda and its Subsidiary Co......II-22
Ranbaxy Receives Approval from FDA.....II-22
Wockhardt Receives FDA Approval for DPN + APAP.....II-22
Alpharma to Market Flector® Patch in the US.....II-22
Auriga and Mikart Inks Agreement to Market Codein.....II-22
1$100
   Watson Receives FDA Approval for Oxycodone Hydrochloride and Ibuprofen.....II-23
Labopharm’s Tramadol Receives Approval in Canada.....II-23
Lion Acquires BUFFERIN® Trademark Rights.....II-23
Grunenthal’s Extends Licensing Agreement with Ortho-McNeil.....II-23
China Aoxing Pockets LRT.....II-23
Anesiva Inks Joint Venture Agreement Wanbang.....II-23
1$100
   Beijing Med-Pharm Inks Agreement with Lotus Healthcare.....II-24
LAB International Inks Licensing Agreement with Janssen Pharmaceutica.....II-24
Three Sixty Pockets Rockford-Montgomery Labs.....II-24
Antares Enters into License and Development Agreement for Opioid Analgesic.....II-24
Abraxis BioScience Acquires AstraZeneca’s Analgesic Brand Portfolio.....II-24
IntelliPharmaCeutics Inks Agreement with Larasan.....II-24
1$100
   Ranbaxy and Ethypharm Ink In-licensing Agreement.....II-25
Elite Collaborates with TPN to Co-develop Analgesic Drug.....II-25
Novartis Acquires Hexal Company and Major Stake in Eon Labs ......II-25
NovaDel Pharma Receives Patent for Buccal Sprays Technology.....II-25
Auxilium Pharmaceuticals Enters into a Licensing Agreement with PharmaForm .....II-25
1$100
   EC Sanctions Sale of Elan’s Prialt.....II-26
EpiCept Corp. Merges with Maxim Pharmaceuticals, Inc.....II-26
Reckitt Benckiser plc Acquires Boots Healthcare International .....II-26
Bayer Acquires Non-prescription Drug Business of Roche .....II-26
1$100
   Bextra (Valdecoxib) Receives Green Signal from Health Canada .....II-27
Rhodia Announces Closure of Acetaminophen Plant in Louisiana.....II-27
NicOx Re-Gains Rights to CINOD from AstraZeneca.....II-27
1$100
  7. Focus on Select Key Players.....II-283 $300  
   Bayer Consumer Care (USA).....II-28
Bristol-Myers Squibb Company (USA).....II-28
Johnson & Johnson (USA).....II-28
McNeil Consumer Healthcare (Canada).....II-28
1$100
   Novartis International AG (Switzerland).....II-29
Pfizer Inc. (USA).....II-29
Reckitt Benckiser Group Plc (UK).....II-29
W. F. Young Inc (USA).....II-29
1$100
   Wyeth (USA).....II-30
Wyeth Consumer Healthcare.....II-30
1$100
  8. Global Market Perspective.....II-31   
   Table 2: World Recent Past, Current & Future Analysis for Analgesics by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-311$350
   Table 3: World Long-term Projections for Analgesics by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-321$350
   Table 4: World Historic Review for Analgesics by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....II-331$350
   Table 5: World 15-Year Perspective for Analgesics by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart).....II-341$350
   Table 6: World Recent Past, Current & Future Analysis for Internal Analgesics by Geographic Region/ Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-351$350
   Table 7: World Long-term Projections for Internal Analgesics by Geographic Region / Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-361$350
   Table 8: World Historic Review for Internal Analgesics by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....II-371$350
   Table 9: World 15-Year Perspective for Internal Analgesics by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart).....II-381$350
   Table 10: World Recent Past, Current & Future Analysis for Internal Analgesics by Product Segment – Aspirin, Acetaminophen, Ibuprofen, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-39

Table 11: World Long-term Projections for Internal Analgesics by Product Segment – Aspirin, Acetaminophen, Ibuprofen, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-39
1$350
   Table 12: World Historic Review for Internal Analgesics by Product Segment – Aspirin, Acetaminophen, Ibuprofen, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....II-40

Table 13: World 15-Year Perspective for Internal Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Aspirin, Acetaminophen, Ibuprofen, and Others Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart).....II-40
1$350
   Table 14: World Recent Past, Current & Future Analysis for Aspirin by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-411$350
   Table 15: World Long-term Projections for Aspirin by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-421$350
   Table 16: World Historic Review for Aspirin by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....II-431$350
   Table 17: World 15-Year Perspective for Aspirin by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart).....II-441$350
   Table 18: World Recent Past, Current & Future Analysis for Acetaminophen by Geographic Region/ Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-451$350
   Table 19: World Long-term Projections for Acetaminophen by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-461$350
   Table 20: World Historic Review for Acetaminophen by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....II-471$350
   Table 21: World 15-Year Perspective for Acetaminophen by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart).....II-481$350
   Table 22: World Recent Past, Current & Future Analysis for Ibuprofen by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-491$350
   Table 23: World Long-term Projections for Ibuprofen by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-501$350
   Table 24: World Historic Review for Ibuprofen by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....II-511$350
   Table 25: World 15-Year Perspective for Ibuprofen by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart).....II-521$350
   Table 26: World Recent Past, Current & Future Analysis for *Other Internal Analgesics by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-531$350
   Table 27: World Long-term Projections for *Other Internal Analgesics by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-541$350
   Table 28: World Historic Review for *Other Internal Analgesics by Geographic Region / Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....II-551$350
   Table 29: World 15-Year Perspective for *Other Internal Analgesics by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart).....II-561$350
   Table 30: World Recent Past, Current & Future Analysis for External Analgesics by Geographic Region/ Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 2010 (includes corresponding Graph/Chart).....II-571$350
   Table 31: World Long-term Projections for External Analgesics by Geographic Region / Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-581$350
   Table 32: World Historic Review for External Analgesics by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 2000 (includes corresponding Graph/Chart).....II-591$350
   Table 33: World 15-Year Perspective for External Analgesics by Geographic Region /Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart).....II-601$350
III-A. MARKET81$1950
  1. The United States.....III-113 $1275  
   A. Market Analysis.....III-1
Current and Future Analysis.....III-1
Pain Statistics in the US.....III-1
Industry Overview.....III-1
1$75
   Internal Analgesics.....III-2
Cox-2 Drugs in for Some Trouble.....III-2
Switch to OTC Drugs.....III-2
Table 34: US Internal Tablet Analgesics Market (2007): Percentage Share Breakdown of Leading Ten Brands by Revenues (includes corresponding Graph/Chart).....III-2
1$200
   Table 35: US Internal Liquid Analgesics Market (2007): Percentage Share Breakdown of Leading Ten Brands by Revenues (includes corresponding Graph/Chart).....III-3

Table 36: Internal Analgesics Market in the U.S. By Retail Channel (2008E): Percentage Share by Value Sales for Discount Stores, Food / Drug Combination Stores, Chain Drug Stores, Supermarkets, and Independent Drug Stores (includes corresponding Graph/Chart).....III-3
Promotional Strategies for the Internal Analgesics.....III-3
Table 37: Market for Internal Liquid Analgesics in the U.S. by Retail Channel (2008E): Percentage Share by Value Sales for Supermarkets, Drug Stores, and Discounters (includes corresponding Graph/Chart).....III-3
1$200
   Pediatric Analgesics: The New Kid on the Block.....III-4
External Analgesics.....III-4
Stretching Boundaries.....III-4
Table 38: US External Analgesics Market (2007): Percentage Share Breakdown of Leading Ten Brands by Revenues (includes corresponding Graph/Chart).....III-4

Table 39: External Analgesics Market in the U.S. By Retail Channel (2008E): Percentage Share by Value Sales for Chain drug stores, Discount stores, Food/drug combination stores, Independent drug stores, and Supermarkets (includes corresponding Graph/Chart).....III-4
Rubs, Patches: Driving the External Analgesics Market.....III-4
1$200
   Patch Relief Gaining Momentum.....III-5
Product Innovations/Introductions.....III-5
1$75
   Strategic Corporate Developments.....III-63$225
   Major Players.....III-92$150
   B. Market Analytics.....III-11
Table 40: US Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-11
1$200
   Table 41: US Long-term Projections for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-12

Table 42: US Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....III-12
1$200
   Table 43: US 15-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart).....III-13
1$200
  2. Canada.....III-145 $575  
   A. Market Analysis.....III-14
Current and Future Analysis.....III-14
Key Players.....III-14
McNeil Consumer Healthcare.....III-14
Product Launches.....III-14
Strategic Corporate Developments.....III-14
2$150
   B. Market Analytics.....III-16
Table 44: Canadian Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-16
1$200
   Table 45: Canadian Long-term Projections for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-17

Table 46: Canadian Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....III-17
1$200
   Table 47: Canadian 15-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart).....III-18
1$200
  3. Japan.....III-195 $775  
   A. Market Analysis.....III-19
Current and Future Analysis.....III-19
Competitive Scenario.....III-19
Table 48: OTC Analgesics Market in Japan (2005): Market Share of Leading Players by Value – Lion, Arax, Taisho Pharmaceutical, SS Pharmaceutical, Shionogi, and Others (includes corresponding Graph/Chart).....III-19
Strategic Corporate Developments.....III-19
2$400
   B. Market Analytics.....III-21
Table 49: Japanese Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-21
1$200
   Table 50: Japanese Long-term Projections for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-22

Table 51: Japanese Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....III-22
1$200
   Table 52: Japanese 15-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart).....III-23
1$200
  4. Europe.....III-247 $875  
   A. Market Analysis.....III-24
Current and Future Analysis.....III-24
By Product Group/Segment.....III-24
European Pain Management Market.....III-24
Generics Restrain Revenue Growth.....III-24
1$75
   Table 53: Popular Brands of Pain & Inflammation Medication in Europe (2004): Percentage Share of Aspirin, Voltaren, Ibuprofen, Nurofen, Vioxx, Celebre, Tylenol, Aulin, Anadin, and Paracetamol (includes corresponding Graph/Chart).....III-251$200
   B. Market Analytics.....III-26
Table 54: European Recent Past, Current & Future Analysis for Analgesics by Geographic Region/Country – France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-26

Table 55: European Long-term Projections for Analgesics by Geographic Region/Country – France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-26
1$200
   Table 56: European Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-27

Table 57: European Long-term Projections for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-27
1$200
   Table 58: European Historic Review for Analgesics by Geographic Region/Country – France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....III-28

Table 59: European Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....III-28
1$200
   Table 60: European 15-Year Perspective for Analgesics by Geographic Region/Country – Percentage Breakdown of Dollar Sales for France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart).....III-291$200
   Table 61: European 15-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart).....III-30
1$200
  4a. France.....III-314 $625  
   A. Market Analysis.....III-31
Current and Future Analysis.....III-31
Competitive Scenario.....III-31
Table 62: Analgesics Market in France (2005): Market Share of Leading Players by Value – Bristol-Myers Squibb, Therapix, Roche, Bayer Group, Wyeth Consumer Healthcare, and Others) (includes corresponding Graph/Chart).....III-31
Key Player.....III-31
Sanofi Aventis.....III-31
1$200
   B. Market Analytics.....III-32
Table 63: French Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-32
1$200
   Table 64: French Long-term Projections for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015(includes corresponding Graph/Chart).....III-33

Table 65: French Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....III-33
1$200
   Table 66: French 15-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart).....III-34
1$200
  4b. Germany.....III-354 $625  
   A. Market Analysis.....III-35
Current and Future Analysis.....III-35
Competitive Scenario.....III-35
Table 67: Analgesics Market in Germany (2005): Market Share of Leading Players by Value – Bayer Group, Boehringer Ingelheim, Wyeth Consumer Healthcare, and Others (includes corresponding Graph/Chart).....III-35
1$200
   B. Market Analytics.....III-36
Table 68: German Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-36
1$200
   Table 69: German Long-term Projections for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-37

Table 70: German Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....III-37
1$200
   Table 71: German 15-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart).....III-38
1$200
  4c. The United Kingdom.....III-394 $625  
   A. Market Analysis.....III-39
Current and Future Analysis.....III-39
Key Player.....III-39
Reckitt Benckiser Group Plc.....III-39
Competitive Scenario.....III-39
Table 72: Analgesics Market in the United Kingdom (2005E): Market Shares of Leading Players by Value – Boots Healthcare, GlaxoSmithKline, and Others (includes corresponding Graph/Chart).....III-39
Ten Leading Analgesics Brands for Children in the UK Analgesics Market.....III-39
Strategic Corporate Developments.....III-39
1$200
   B. Market Analytics.....III-40
Table 73: UK Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-40
1$200
   Table 74: UK Long-term Projections for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015(includes corresponding Graph/Chart).....III-41

Table 75: UK Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....III-41
1$200
   Table 76: UK 15-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart).....III-42
1$200
  4d. Italy.....III-434 $625  
   A. Market Analysis.....III-43
Current and Future Analysis.....III-43
Competitive Scenario.....III-43
Table 77: Analgesics Market in Italy (2005): Market Share of Leading Players by Value – Bayer Group, Angelini, Novartis, Bristol-Myers Squibb, and Others (includes corresponding Graph/Chart).....III-43
1$200
   B. Market Analytics.....III-44
Table 78: Italian Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-44
1$200
   Table 79: Italian Long-term Projections for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-45

Table 80: Italian Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....III-45
1$200
   Table 81: Italian 15-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart).....III-46
1$200
  4e. Spain.....III-474 $625  
   A. Market Analysis.....III-47
Current and Future Analysis.....III-47
Competitive Scenario.....III-47
Table 82: Analgesics Market in Spain (2005): Market Share of Leading Players by Value – Bayer Group, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Boots Healthcare, and Others (includes corresponding Graph/Chart).....III-47
1$200
   B. Market Analytics.....III-48
Table 83: Spanish Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-48
1$200
   Table 84: Spanish Long-term Projections for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015(includes corresponding Graph/Chart).....III-49

Table 85: Spanish Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....III-49
1$200
   Table 86: Spanish 15-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart).....III-50
1$200
  4f. Rest of Europe.....III-515 $575  
   A. Market Analysis.....III-51
Current and Future Analysis.....III-51
Product Innovations/Introductions.....III-51
Strategic Corporate Developments.....III-51
1$75
   Key Player.....III-52
Novartis International AG (Switzerland).....III-52
1$75
   B. Market Analytics.....III-53
Table 87: Rest of Europe Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-53
1$200
   Table 88: Rest of Europe Long-term Projections for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-54

Table 89: Rest of Europe Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....III-54
1$200
   Table 90: Rest of Europe 15-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart).....III-55
1$200
  5. Asia-Pacific.....III-565 $575  
   A. Market Analysis.....III-56
Current and Future Analysis.....III-56
The OTC Analgesic Market.....III-56
OTC Analgesics Market in Asia-Pacific (2004): A Comparative Analysis of the Major
  Regions – Australia, China and South Korea.....III-56
Aspirin – The Chinese Market.....III-56
1$75
   Strategic Corporate Developments.....III-571$75
   B. Market Analytics.....III-58
Table 91: Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-58
1$200
   Table 92: Asia-Pacific Long-term Projections for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-59

Table 93: Asia-Pacific Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....III-59
1$200
   Table 94: Asia-Pacific 15-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart).....III-60
1$200
  6. Latin America.....III-613 $475  
   A. Market Analysis.....III-61
Current and Future Analysis.....III-61
B. Market Analytics.....III-61
Table 95: Latin American Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-61
1$200
   Table 96: Latin American Long-term Projections for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-62

Table 97: Latin American Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....III-62
1$200
   Table 98: Latin American 15-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart).....III-63
1$200
  7. Rest of World.....III-643 $425  
   A. Market Analysis.....III-64
Current and Future Analysis.....III-64
Strategic Corporate Developments.....III-64
B. Market Analytics.....III-64
Table 99: Rest of World Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-64
1$200
   Table 100: Rest of World Long-term Projections for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-65

Table 101: Rest of World Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart).....III-65
1$200
   Table 102: Rest of World 15-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart).....III-66
1$200
  III-B. APPENDIX – POPULAR ANALGESIC BRANDS BY REGION.....III-6715 $1125  
   Canada.....III-67
France.....III-67
1$75
   Germany.....III-681$75
   United Kingdom.....III-691$75
   Leading Analgesics Brands for Children.....III-70
Italy.....III-70
Spain.....III-70
1$75
   Rest of Europe.....III-716$450
   Asia-Pacific.....III-774$625
   Latin America.....III-814$625
IV. COMPETITIVE LANDSCAPE 350$995
  
Total Companies Profiled: 139 (including Divisions/Subsidiaries - 179)

Region/Country                 Players


The United States                 48
Canada                             4
Japan                              8
Europe                            55
     France                        4
     Germany                       9
     The United Kingdom           13
     Italy                         8
     Spain                         2
     Rest of Europe               19
Asia-Pacific (Excluding Japan)    52
Africa                             2
Middle East                       10
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2010, Global Industry Analysts, Inc., USA.